GS1, Healthcare, and Axway

Bruno Cambounet, VP Sales and Operations EMEA, Supply Chain Vertical Markets, Axway

“We have found, when implementing our track and trace solution, which is GS1 compliant, we have been facing, and we are still facing, and we are going to be faced with very different regulations.”

Futureproofing Our Information Exchange Infrastructure

Ruby Raley, Director, Healthcare Solutions, Axway

“Many, many folks are challenged by anything more technical than email. And many other folks are adopting almost an R&D approach to eMR implementation, where they’re trying to real-time enable ambulances to pull records. And when a patient arrives at an emergency department, an ED…they’re able to pull that patient’s health record up on the fly in real time.”

Beyond the Scope

by Ruby Raley, Director, Healthcare Solutions, Axway

You may have been following some of the recent articles on pharmaceutical distribution, and, in particular, the conversation on anti-counterfeiting that appeared in USA Today. Another article, this one in The Wall Street Journal, appeared around the same time and took a very different point of view: that counterfeits are not a serious problem.

So, if you’re an executive, a leader, or someone who cares about the safety of our pharmaceutical distribution supply chain, what are you supposed to glean from all these messages from respected voices?

Consider the recent injury of a diabetic man, an injury that had nothing to do with counterfeit pharmaceuticals yet illustrates why anti-counterfeiting measures can yield effects that go beyond the scope of pharmaceuticals.

A shipment of diabetes management devices was stolen from a major manufacturer’s truck, and the lot the devices belonged to didn’t appear in the marketplace at all for a year.

Then, all of a sudden, it did. A patient purchased one of the devices, the device was no longer effective, the test did not work correctly, and the patient’s blood sugar went sky high.

This episode succinctly illustrates why we should be concerned about anti-counterfeit measures, regardless of contrarian pragmatists with narrowly focused points of view. Whether the root cause is the bad guys making fake product and putting it in the supply chain, or the bad guys stealing product and mishandling the product and putting it back in the supply chain, or non-pedigreed product coming over the border and into our pharmacies, there is a problem.

And fortunately, we actually know how to solve that problem.

Tighter lot control.

The lots are so large now that when there’s a recall, it can clear the shelves, as you’ve probably seen at your local pharmacy with some of the recent recalls from trusted manufacturers.

We need smaller lots, and we need to assign a serialized number to the product below the overall lot level so that we can track batches and sub-shipments. With the right software, tracking those batches and sub-shipments is not difficult, yet the savings compared to entire lot recalls is profound.

And with track and trace legislation enforcement just five years away, product manufacturers should seriously consider labeling at the case level or at the shipment level, using tamper-evident markings, and investing in the right solutions so that they can determine that all products have shipped safely from a secure manufacturing site to a secure distributor, or from a secure distributor to a secure location at a local pharmacy.

After all, there’s a lot more than profit margins and reputations at stake. And the sooner everyone—journalists, enterprises, and industry leaders alike—recognize that even one injury injures us all, the sooner profit margins, reputations, and a lot more can be secured.

Protecting the Reputations of Our Firms, Industries, and Departments

Ruby Raley, Director, Healthcare Solutions, Axway

“We are tasked with making sure that those messages, that information, moves safely and securely to the person who needs it to provide the care to the patient, to deliver the service the patient needs, to deliver the test the patient needs in order to help the doctor make the right diagnosis. IT is the enabler through information exchange for so many interactions that improve healthcare and improve the quality of life of everyone.”

Life Sciences on Demand

Ruby Raley, Director, Healthcare Solutions, Axway

The HIPAA 5010 and ICD-10 Migration

Ruby Raley, Director, Healthcare Solutions, Axway

The HIPAA 5010 and ICD-10 Migration, Pt. 1

The HIPAA 5010 and ICD-10 Migration, Pt. 2

Just Waiting for 2015?: Serialization in the Pharmaceutical Supply Chain

Ruby Raley, Director, Healthcare Solutions, Axway